The EU Commission clears acquisition of fourth largest global manufacturer of generic medicines by the largest global competitor, subject to complex remedies and monitoring, including addressing concerns about vertical relationships between parties for the first time in a generics merger (Teva / Allergan Generics)

Teva/Allergan Generics: An unprecedented generics merger* In a nutshell While the Commission has had significant experience dealing with mergers in the generic medicines industry, the sheer scale of Teva/Allergan Generics, combining two of the top four players globally, posed a number of interesting challenges. The Commission assessed competitive dynamics beyond product-by-product overlaps at the level of the overall sale of generics in a Member State, and identified serious doubts in the UK, Ireland and Iceland. For the first time, it deemed certain vertical aspects of a generics transaction problematic. Finally, the remedy design and monitoring also brought their share of complexity, requiring innovative ad hoc approaches. 1. Overview In March 2016, the Commission cleared the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • DG COMP (Brussels)
  • DG COMP (Brussels)
  • DG COMP (Brussels)
  • Spanish Ministry of Economy, Industry and Competitiveness (Madrid)

Quotation

Marion Bailly, Ivan Gasperec, Arthur Stril, Noa Laguna-Goya, The EU Commission clears acquisition of fourth largest global manufacturer of generic medicines by the largest global competitor, subject to complex remedies and monitoring, including addressing concerns about vertical relationships between parties for the first time in a generics merger (Teva / Allergan Generics), 10 March 2016, e-Competitions March 2016, Art. N° 86459

Visites 171

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues